Skip to main content
SpringerLink
Log in

Medical Disease After Abdominal Solid Organ Transplantation and the Risk of Solid and Hematologic Malignant Tumor After Transplantation

  • Chapter
Abdominal Solid Organ Transplantation

  • 1436 Accesses

Abstract

Solid organ transplantation is the treatment of choice for selected patients with end-stage organ insufficiency. Currently, the survival of patients after kidney and liver transplantation exceeds respectively 80 and 70% after 5 years, associated in the majority of cases with a good quality of life. While in the early postoperative period the main causes of morbidity and mortality are related to the primary organ dysfunction, surgical complications or postoperative infection, in the long term they are mainly related to the emergence of disorders linked to immunosuppressive therapy side effects or to primary disease recurrence. Monitoring immunosuppressive drug blood levels is a key point in the management of patients after solid organ transplantation in order to minimize the potential adverse effects. However, careful management of potentially modifiable risk factors such as metabolic syndrome, cardiovascular diseases and renal insufficiency may improve long-term survival.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Pfitzmann R, Nüssler N, Hippler-Benscheidt M, Neuhaus R, Neuhaus P. Long-term results after liver transplantation. Transpl Int. 2008;21(3):234–46.

    Article  PubMed  Google Scholar 

  2. Westbrook RH, Yeoman AD, Agarwal K, Aluvihare V, Mieli- Vergani G, Dhawan A, et al. An evaluation of mortality in adults and children who have survived in excess of 5 and 10 years since liver transplantation [abstract]. Liver Transpl. 2009;15 suppl 7:S101.

    Google Scholar 

  3. Meier-Kriesche HU, et al. Immunosuppression: evolution in practice and trends, 1994–2004. Am J Transplant. 2006;6:1111–31.

    Article  CAS  PubMed  Google Scholar 

  4. Kasiske B, Guijarro C, Massy Z, Wiederkehr M, Ma J. Cardiovascular disease after renal transplantation. J Am Soc Nephrol. 1996;7:158–65.

    CAS  PubMed  Google Scholar 

  5. Grundy S, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–52.

    Article  PubMed  Google Scholar 

  6. Tellez-Avila F, Sanchez-Avila F, Garcia-Saenz-de-Socolia M, Chavez-Tapia NC, Granco-Gusman AM, Lopez-Arce G, et al. Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World J Gastroenterol. 2008;14:4771–5.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Soveri I, Abedini S, Holdaas H, Jardine A, Eriksson N, Fellström B. Graft loss risk in renal transplant recipients with metabolic syndrome: subgroup analyses of the ALERT trial. J Nephrol. 2012;25(02):245–54.

    Article  CAS  PubMed  Google Scholar 

  8. Anastacio LR, Diniz KG, Ribeiro HS, Ferreira LG, Lima AS, Correia MI, Vilela EG. Prospective evaluation of metabolic syndrome and its components among long-term liver recipients. Liver Int. 2014;11:5–8.

    Google Scholar 

  9. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52.

    Article  PubMed  Google Scholar 

  10. Poonawala A, Nair S, Thuluvath P. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology. 2000;32:689–92.

    Article  CAS  PubMed  Google Scholar 

  11. Leonarda J, Heimbachb JK, Malinchocc M, Watta K, Charlton M. The impact of obesity on long-term outcomes in liver transplant recipients—results of the NIDDK liver transplant database. Am J Transplant. 2008;8:667–72.

    Article  Google Scholar 

  12. Hoogeveen EK, Aalten J, Rothman KJ, et al. Effect of obesity on the outcome of kidney transplantation: a 20-year follow-up. Transplantation. 2011;91:869–74.

    Article  PubMed  Google Scholar 

  13. Massy ZA. Hyperlipidemia and cardiovascular disease after organ transplantation. Transplantation. 2001;72:S13–5.

    Article  CAS  PubMed  Google Scholar 

  14. Stegall MD, Everson G, Schroter G, et al. Metabolic complications after liver transplantation. Diabetes, hypercholesterolaemia, hypertension, and obesity. Transplantation. 1995;60:1057.

    CAS  PubMed  Google Scholar 

  15. Duclos A, Flachner IM, Faiman C, et al. Post-transplant diabetes mellitus: risk reduction strategies in the elderly. Drugs Aging. 2006;23:781–93.

    Article  CAS  PubMed  Google Scholar 

  16. Heisel O, et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant. 2004;4:583–95.

    Article  PubMed  Google Scholar 

  17. Sharif A, Moore RH, Baboolal K. The use of oral glucose tolerance tests to risk stratify for new-onset diabetes after transplantation: an underdiagnosed phenomenon. Transplantation. 2006;82:1667–72.

    Article  PubMed  Google Scholar 

  18. Madhwal R, Atreja A, Albeldawdi M, Lopez R, Post A, Costa MA. Is liver transplantation a risk factor for cardiovascular disease? a meta-analysis of observational studies. Liver Transpl. 2012;18:1140–6.

    Article  PubMed  Google Scholar 

  19. Beyer N, Aadahl M, Strange B, Kirkegaard P, Hansen BA, Mohr T, Kjaer M. Improved physical performance after orthotopic liver transplantation. Liver Transpl Surg. 1999;5:301–9.

    Article  CAS  PubMed  Google Scholar 

  20. Krasnoff JB, Vintro AQ, Ascher NL, Bass NM, Paul SM, Dodd MJ, Painter PL. A randomized trial of exercise and dietary counseling after liver transplantation. Am J Transplant. 2006;6:1896–905.

    Article  CAS  PubMed  Google Scholar 

  21. Painter P, Krasnoff J, Paul SM, Ascher NL. Physical activity and health-related quality of life in liver transplant recipients. Liver Transpl. 2001;7:213–9.

    Article  CAS  PubMed  Google Scholar 

  22. Sennesael JJ, Lamote JG, Violet I, Tasse S, Verbeelen DL. Divergent effects of calcium channel and angiotensin converting enzyme block- ade on glomerulotubular function in cyclosporine-treated renal allograft recipients. Am J Kidney Dis. 1996;27(5):701–8.

    Article  CAS  PubMed  Google Scholar 

  23. Cross NB, Webster AC, Masson P, O’connell PJ, Craig JC. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation. 2009;88(1):7–18.

    Article  CAS  PubMed  Google Scholar 

  24. Grazi IF, et al. Statins and solid organ transplantation. Curr Pharm Des. 2006;12:4771–83.

    Article  Google Scholar 

  25. Ojo AO, Held PJ, Port KF, Robert A, Wolfe MS, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931–40.

    Article  CAS  PubMed  Google Scholar 

  26. Textor SC, Burnett Jr JC, Romero JC, Canzanello VJ, Taler SJ, Wiesner R, Porayko M, Krom R, Gores G, Hay E. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int. 1995;47(5):1426–33.

    Article  CAS  PubMed  Google Scholar 

  27. Eckhoff DE, McGuire B, Sellers M, Contreras J, Frenette L, Young C, Hudson S, Bynon JS. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. Transplantation. 2000;69(9):1867–72.

    Article  CAS  PubMed  Google Scholar 

  28. Kornberg A, Kupper B, Hommann M, Scheele J. Introduction of MMF in conjunction with stepwise reduction of calcineurin inhibitor in stable liver transplant patients with renal dysfunction. Int Immunopharmacol. 2005;5:141–6.

    Article  CAS  PubMed  Google Scholar 

  29. Biselli M, Vitale G, Gramenzi A, et al. Two year mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant. Clin Transplant. 2009;23:191–8.

    Article  PubMed  Google Scholar 

  30. Castroagudin JF, Molina E, Romero R, et al. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Liver Transpl. 2009;15:1792–7.

    Article  PubMed  Google Scholar 

  31. Penn I. Cancers complicating organ transplantation. N Engl J Med. 1990;323(25):1767–9.

    Article  CAS  PubMed  Google Scholar 

  32. Pruthi J, Medkiff KA, Esrason KT, Donovan JA, Yoshida EM, Erb SR, Steinbrecher UP, Fong TL. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl. 2001;7:811.

    Article  CAS  PubMed  Google Scholar 

  33. Haagsma EB, Hagens VE, Schaapveld M, van den Berg AP, de Vries EG, Klompmaker IJ, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol. 2001;34:84–91.

    Article  CAS  PubMed  Google Scholar 

  34. Goh A, Vathsala A. Native renal cysts and dialysis duration are risk factors for renal cell carcinoma in renal transplant recipients. Am J Transplant. 2011;11:86–92.

    Article  CAS  PubMed  Google Scholar 

  35. Herrero JI. De novo malignancies following liver transplantation: impact and recommendations. Liver Transpl. 2009;15:S90–4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UO Internal Medicine for the Treatment of Severe Organ Insufficiency, Organ Insufficiency and Transplantation, Massarenti 9, Bologna, Italy

    Maria Cristina Morelli

Authors
  1. Maria Cristina Morelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Cristina Morelli .

Editor information

Editors and Affiliations

  1. Surgery and Transplantation, Sant'Orsola Malpighi Hospital, Bologna, Bologna, Italy

    Antonio Daniele Pinna

  2. Surgery and Transplantation, Sant'Orsola Malpighi Hospital, Bologna, Bologna, Italy

    Giorgio Ercolani

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Morelli, M.C. (2015). Medical Disease After Abdominal Solid Organ Transplantation and the Risk of Solid and Hematologic Malignant Tumor After Transplantation. In: Pinna, A., Ercolani, G. (eds) Abdominal Solid Organ Transplantation. Springer, Cham. https://doi.org/10.1007/978-3-319-16997-2_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-16997-2_5

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-16996-5

  • Online ISBN: 978-3-319-16997-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation